Dr. Richard Cummings receives the 2019 IGO Award from the International Glycoconjugate Organization for his exceptional contributions to the field of glycobiology.
SBIR funding by the NHLBI to Selexys results in the development of crizanlizumab. Selexys was founded in 2002 by Rodger (Rod) McEver, M.D., Richard Cummings, Ph.D., and Rick Alvarez, M.B.A. Read...
The deadline for submission of poster abstracts to the 2018 conference on Sialic Acids has been extended to Friday March 30th. This biennial conference is being held May 10...